Further to the previous Emerade drug warning. The Medicines and Healthcare Products Regulatory Agency has warned that some Emerade auto-injector adrenaline pens may be defective. The UK distributor, Bausch & Lomb UK Limited is recalling all unexpired batches due to an error in which the auto-injector pens fail to activate and deliver adrenaline. The advice for healthcare professionals is:
- Stop supplying the affected products immediately
- Quarantine all remaining stock
- Return them to your supplier using your supplier’s approved process.
Emerade stock held by patients is not being recalled.
Affected products:
Emerade 150 micrograms solution for injection in pre-filled syringe PL 33616/0013
Emerade 300 micrograms solution for injection in pre-filled syringe PL 33616/0014
Emerade 500 micrograms solution for injection in pre-filled syringe PL 33616/0015
The advice in the UK is that those of you who have been supplied with Emerade pens should continue to use the pens as instructed. Most Emerade pens will activate as normal; however, you are still advised to carry two in date pens with you at all times. When the Emerade pen has expired, you should then be prescribed a different brand (EpiPen or Jext)
Our anaphylaxis course covers the use of Epi-Pens, Emerade and Jext as well as recognition of signs, treatment and concerns. Training is available as a video online or face to face course nationwide. Find more information on the course here www.proanaphylaxis.co.uk or give us a call on 01206 805359.